



Proven in Large Global Breast Cancer Programs

Your breast cancer trials deserve a provider who delivers, even in the most dynamic global landscapes.



Early Phase I/II | Large-Scale Phase III & Registrational | HR+ / HER2+ / TNBC / Metastatic | High Performing Site Network (EPON) | Biomarker & Precision Medicine Expertise Experience

CORE CAPABILITIES

Translational and Biomarker

End-to-end biomarker-driven strategy, from protocol design through execution. Our experience spans inclusion of patients with broad biomarker profiles from hormone receptor-positive (HR+)/HER2-negative disease, triple-negative breast cancer (TNBC), HER2-positive and HER2-low populations, and studies involving genomic biomarker selection such as PIK3CA, AKT1, and PTEN alterations, as well as PD-L1 and TROP2-driven. Selection of centres that perform these analyses routinely and willing to invest the time and resources to find that one rare patient defines FORTREAs EPON network in early phase to the global community of sites in later phase.

Biomarker-driven design | Molecularly selected cohorts
| CDx integration | Precision oncology execution

Site Network and Enrolment

Pre-qualified oncology site network with strong KOL relationships and active breast cancer pipelines across US, EU and APAC, reducing activation lag significantly.

EPON collaboration network | 70+ high-performing oncology sites | Early-phase experience | Strong referral pipelines

5-YEAR OVERVIEW

Proven delivery at the scale of the largest global breast cancer trials



117 Breast cancer studies in last five years



34k+ Patients enrolled globally



500+ Sites



5 Registrational-Intent Breast Cancer Studies

*2021-2025 Fortrea internal metrics.

Patient-Centricity, Diversity and PRE Excellence

Patient Recruitment and Engagement (PRE) strategies designed for breast cancer trials, integrating patient advocacy collaborations, culturally tailored outreach, diversity-focused recruitment, and biomarker testing support to optimize recruitment performance into the trial, as well as retention on the trial.

Diversity plans (design–execution–reporting) | Real-time monitoring | Global patient access | Inclusive recruitment

Integrating actionable Data Insights, Medical Experience + Operational Excellence

Backed by a global team of 50+ medical Oncology specialists, with deep involvement from design through execution with strategy and operational planning.

Integrated medical-operational delivery | Protocol optimization | Scientific + operational alignment

Trusted, Predictable Delivery

Integrated delivery excellence powered by actionable data insights guiding operational delivery strategy, to dedicated biostatistics, regulatory, and market access specialists supporting high-quality execution, patient enrolment continuity, and robust data generation in complex and rapidly evolving clinical environments.

Adaptive delivery model | Protocol flexibility | Resilient enrolment | Complex trial execution


Integrated Vendor and CDx Ecosysteme

Experienced management of complex multi-vendor environments — integrating, imaging, companion diagnostics, radiopharmaceutical supply chains, and specialised manufacturing logistics with end-to-end oversight and data transparency..


CDx + lab integration | Multi-vendor coordination | End-to-end oversight | Data transparency | Radiopharmaceutical supply & handling | Manufacturing logistics coordination



OUR PROCESS — FROM STRATEGY TO SUBMISSION



Indication depth



Why sponsors choose us

- ✓ Trusted, predictable delivery in complex breast cancer trials
- ✓ Scalable global execution with strong monitoring and control
- ✓ Faster start-up and assured enrollment timelines
- ✓ Real-time visibility and proactive risk management
- ✓ **EMA, FDA, NMDA, PMDA experience** – single CRO for global submissions
- ✓ Flexible FSP or full-service engagement models allows you to decide the best delivery model

FORTREA – COMBINING SCIENTIFIC LEADERSHIP WITH DELIVERY EXCELLENCE

50+

Oncology
Peer Reviewed
Publications*
(2020–2026)

12+

Breast Cancer-
Specific Studies

8+

High-Impact
Oncology
Journals

*Our scientific and clinical teams co-author in journals such as JCO, Lancet Oncology, and Breast Cancer Research — reflecting hands-on therapeutic depth, not just operational delivery.

Global Regulatory Experience

- 65 oncology agency interactions across FDA, EMA, PMDA and NMPA (2020–2025)
- FDA Fast Track Designation support for HER2-positive breast cancer
- Experience supporting accelerated development pathways
- Rolling NDA and global submission support

Case study

[Story of largest global breast cancer mega trial](#)

Article

[Combining multiple therapies for metastatic breast cancer](#)

Publication

[Peer reviewed journal article by Fortrea oncologists](#)

Let's accelerate your breast cancer program.

Request a feasibility assessment or therapeutic area overview deck, or talk to our team.

[DISCOVER MORE](#)

Together Exceptional is possible...



BOOK A MEETING at fortrea.com